{"url":"https://lda.senate.gov/api/v1/filings/ee2d98aa-ebe5-46f9-a669-01cb84049d4e/","filing_uuid":"ee2d98aa-ebe5-46f9-a669-01cb84049d4e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/ee2d98aa-ebe5-46f9-a669-01cb84049d4e/print/","filing_document_content_type":"text/html","income":"10000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mark Lindsay","dt_posted":"2026-07-20T16:50:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"425 3rd St SW # 1250","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":400395867,"url":"https://lda.senate.gov/api/v1/registrants/400395867/","house_registrant_id":null,"name":"BELL & LINDSAY, INC.","description":"Lobbying and Consulting","address_1":"425 3rd St SW # 1250","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK LINDSAY","contact_telephone":"+1 202-905-7345","dt_updated":"2026-07-20T17:09:31.798065-04:00"},"client":{"id":67356,"url":"https://lda.senate.gov/api/v1/clients/67356/","client_id":67356,"name":"DEMERX, INC","general_description":"Clinical stage drug development company","client_government_entity":null,"client_self_select":false,"state":"FL","state_display":"Florida","country":"US","country_display":"United States of America","ppb_state":"FL","ppb_state_display":"Florida","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-05-22"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"advocacy and education around the company's value proposition to advance medicines to break the cycle of alcohol and drug dependence.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":49748,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":"F","last_name":"LINDSAY","suffix":null,"suffix_display":null},"covered_position":"U.S House Staff","new":false},{"lobbyist":{"id":145003,"prefix":null,"prefix_display":null,"first_name":"ERIK","nickname":null,"middle_name":null,"last_name":"DELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}